Virtual Poster Session: Key Data on NETs Presented During the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting
Virtual Poster
Virtual Poster

Virtual Poster Session: Key Data on NETs Presented During the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View slides and abstract presentations covering the most up-to-date clinical trial data of neuroendocrine tumors from the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

2.5 AMA PRA Category 1 Credits™

Release Date

Release Date

Mar 15, 2017

Expiration Date

Mar 16, 2018

Angela Lamarca, MD

Abstract #H9: PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs)
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Angela Lamarca, MD

Diego Ferone, MD, PhD

Abstract #K1: Safety and Efficacy of High Dose Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Diego Ferone, MD, PhD

Raj Srirajaskanthan, MD, MRCP

Abstract #K16: Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Raj Srirajaskanthan, MD, MRCP

Alexandria Phan, MD

Abstract #K18: Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Alexandria Phan, MD

James C. Yao, MD

Abstract #L19: An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: James C. Yao, MD

Jennifer Chan, MD, MPH

Abstract #228: Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Jennifer Chan, MD, MPH

Simron Singh, MD

Abstract #285: Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Simron Singh, MD

Jonathan Strosberg, MD

Abstract #348: Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Jonathan Strosberg, MD

George A Fisher, MD

Abstract #378: Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: George A Fisher, MD

Alexandria Phan, MD

Abstract #398: Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Alexandria Phan, MD

  • Jennifer Chan, MD, MPHDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Diego Ferone, MD, PhDUniversity of Genova
    Genova, Italy
  • George A Fisher, MDStanford University School of Medicine
    Stanford, California, United States
  • Angela Lamarca, MDThe Christie NHS Foundation Trust
    Manchester, United Kingdom
  • Alexandria Phan, MDHouston Methodist Hospital
    Houston, Texas, United States
  • Simron Singh, MDSunnybrook Health Sciences Centre
    Toronto, Canada
  • Raj Srirajaskanthan, MD, MRCPKing's College Hospital
    London, United Kingdom
  • Jonathan Strosberg, MDMoffitt Cancer Center
    Tampa, Florida, United States
  • James C. Yao, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States

This educational activity is supported by IPSEN.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Cremolini has disclosed that she has received consulting fees from Bayer and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Demetri has disclosed that he has received consulting fees from Ariad, Astra-Zeneca, Bayer, Bessor Pharmaceuticals (uncompensated), Bind Therapeutics, Blueprint Medicines (scientific advisory board), Caris (scientific advisory board), Champions Oncology (scientific advisory board), Daiichi-Sankyo, EMD-Serono, G1 Therapeutics (scientific advisory board), Glaxo-Smith-Kline, Janssen Oncology, Kolltan Pharmaceuticals (scientific advisory board), Pfizer, Polaris Pharmaceuticals, Sanofi Oncology, WIRB Copernicus Group, and ZioPharm. He has also performed contracted research support for Dana-Farber for specific clinical trial agreements in the sarcoma unit for Bayer, EMD-Serono, Glaxo-Smith-Kline, Janssen Oncology, Novartis, Pfizer, and Sanofi Oncology. He has equity minor stake, non-public in , Bessor Pharmaceuticals Blueprint Medicines, Champions Oncology, G1 Therapeutics, and Kolltan Pharmaceuticals. He has equity minor stake, public in Caris. He has received royalties paid to Dana-Farber and patent licensed to Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grothey has disclosed that he has performed contracted research for Bayer, Eisai, Eli-Lilly, Genentech, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Ilson has disclosed that he has received consulting fees from Amgen, Bayer, and Lilly. He has also performed contracted research for Amgen, Bayer, and Bristol-Myers Squibb. He has received fees for non-CME services from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Ng has disclosed that she has received consulting fees from Genentech, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation. 

Dr Palmer has disclosed that he has received consulting fees from Bayer and Boehringer Ingelheim. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Peeters has disclosed that he has received fees for non-CME services from Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Rivera has disclosed that he has received consulting fees from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Shah has disclosed that he has stocks in Gilead and Pfizer. He has received fees for speaking for Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Siena has disclosed that he has received consulting fees from Amgen, Bayer, Ignyta Pharmaceuticals, Roche, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Stintzing has disclosed that he has received consulting fees from Amgen, Bayer, Genentech, Merck Serono, Roche, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Thomas has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation. 

Dr Tomasello has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

Dr Zhu has disclosed that he has received consulting fees from Celgene, Eisai, Exelixis, and Sanofi-Aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. 

The employees of prIME Oncology have disclosed:

  • Chelsey Goins, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, BSN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships